Skip to main content

Aryeh Jason's Form 4 filing

Ligand Pharmaceuticals IncLGND · filed Nov 12, 2026

Accession no.
0001376960-26-000008
Filed
Nov 12, 2026, 4:49 PM ET
Trade date
Nov 10, 2026
Filing delay
2 days
Rule 10b5-1 plan
Not checked

This filing lists 6 non-derivative transactions. Open-market sales total $960.1K. It was filed 2 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
Aryeh JasonCIK 0001376960Director

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 10, 2026Common StockSSaleDisposed−500$319.99−$159,995107,976Direct
Nov 10, 2026Common StockSSaleDisposed−844$320.00−$270,075.78107,132Direct
Nov 10, 2026Common StockSSaleDisposed−646$320.00−$206,720106,486Direct
Nov 10, 2026Common StockSSaleDisposed−10$320.02−$3,200.2106,476Direct
Nov 10, 2026Common StockSSaleDisposed−500$320.10−$160,050105,976Direct
Nov 10, 2026Common StockSSaleDisposed−500$320.20−$160,100105,476Direct

Footnotes and remarks

Livermore keeps the footnotes that transaction prices refer to, all footnotes of amendments (Form 4/A) and the filing's remarks. Other footnotes, such as how indirect holdings are held or the details of a trading plan, are only in the original on SEC EDGAR.

No transaction price on this filing refers to a footnote.

Read the full filing on SEC EDGAR (opens in a new tab)